AMIR MORADI
- Type
- Physician · Allopathic & Osteopathic Physicians / Otolaryngology
- Where
- VISTA, CA
- NPI
- 1467567032
- Received
- $477,365 in 555 records, 2019 to 2025 ($389,280 general, $88,085 research)
- As principal investigator
- $2,192,714 of research payments to others in 199 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 71 | $99,578 |
| 2025 | Research payment | 10 | $1,096 |
| 2024 | General payment | 57 | $40,384 |
| 2024 | Research payment | 7 | $5,554 |
| 2023 | General payment | 142 | $106,462 |
| 2023 | Research payment | 22 | $76,870 |
| 2022 | General payment | 84 | $54,408 |
| 2022 | Research payment | 6 | $383 |
| 2021 | General payment | 41 | $25,313 |
| 2021 | Research payment | 8 | $4,181 |
| 2020 | General payment | 52 | $21,079 |
| 2019 | General payment | 55 | $42,053 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| ABBVIE INC. | 335 | $248,241 | 2021–2025 |
| MERZ NORTH AMERICA, INC. | 42 | $114,749 | 2019–2025 |
| Allergan, Inc. | 157 | $89,384 | 2019–2023 |
| Galderma Laboratories, L.P. | 16 | $24,842 | 2020–2025 |
| REVANCE THERAPEUTICS, INC. | 4 | $100 | 2024 |
| Endo Pharmaceuticals Inc. | 1 | $45 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Consulting Fee | 62 | $322,365 |
| Research payment | 53 | $88,085 |
| Travel and Lodging | 61 | $29,427 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 54 | $26,635 |
| Food and Beverage | 220 | $8,461 |
| Education | 105 | $2,389 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-18 | ABBVIE INC. | $281 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-12-04 | MERZ NORTH AMERICA, INC. | $22,968 | Consulting Fee | Cash or cash equivalent | Xeomin Biological, Dermatology | 2025 | |
| 2025-12-04 | ABBVIE INC. | $15,525 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-04 | ABBVIE INC. | $10,235 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-04 | MERZ NORTH AMERICA, INC. | $6,264 | Consulting Fee | Cash or cash equivalent | Xeomin Biological, Dermatology | 2025 | |
| 2025-12-04 | MERZ NORTH AMERICA, INC. | $2,000 | Travel and Lodging | Cash or cash equivalent | Xeomin Biological, Dermatology | 2025 | |
| 2025-12-04 | ABBVIE INC. | $156 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-04 | ABBVIE INC. | $113 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-12-04 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-11-13 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-11-10 | ABBVIE INC. | $85 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-03 | ABBVIE INC. | $9 | Education | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-11-03 | ABBVIE INC. | $9 | Education | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-11-03 | ABBVIE INC. | $9 | Education | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-11-03 | ABBVIE INC. | $9 | Education | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-11-03 | ABBVIE INC. | $9 | Education | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-11-03 | ABBVIE INC. | $9 | Education | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-11-03 | ABBVIE INC. | $9 | Education | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-11-03 | ABBVIE INC. | $9 | Education | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-11-03 | ABBVIE INC. | $9 | Education | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-11-03 | ABBVIE INC. | $9 | Education | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-11-01 | ABBVIE INC. | $375 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-01 | ABBVIE INC. | $50 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-01 | ABBVIE INC. | $50 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-01 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-01 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-31 | ABBVIE INC. | $7,187 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-31 | ABBVIE INC. | $204 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-28 | ABBVIE INC. | $4,005 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-26 | ABBVIE INC. | $103 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-25 | ABBVIE INC. | $56 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-25 | ABBVIE INC. | $48 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-25 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-25 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-24 | ABBVIE INC. | $368 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-24 | ABBVIE INC. | $109 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-21 | ABBVIE INC. | $33 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-10-08 | ABBVIE INC. | $93 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-04 | ABBVIE INC. | $656 | Research payment | In-kind items and services | A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scar | 2025 | |
| 2025-10-04 | ABBVIE INC. | $53 | Research payment | In-kind items and services | A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scar | 2025 | |
| 2025-10-04 | ABBVIE INC. | $49 | Research payment | In-kind items and services | A Study To Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants with Atrophic Acne Scar | 2025 | |
| 2025-10-04 | ABBVIE INC. | $32 | Research payment | In-kind items and services | A Study To Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants with Atrophic Acne Scar | 2025 | |
| 2025-10-04 | ABBVIE INC. | $21 | Research payment | In-kind items and services | A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scar | 2025 | |
| 2025-10-03 | ABBVIE INC. | $125 | Research payment | In-kind items and services | A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scar | 2025 | |
| 2025-10-03 | ABBVIE INC. | $68 | Research payment | In-kind items and services | A Study To Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants with Atrophic Acne Scar | 2025 | |
| 2025-10-03 | ABBVIE INC. | $46 | Research payment | In-kind items and services | A Study To Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants with Atrophic Acne Scar | 2025 | |
| 2025-09-16 | ABBVIE INC. | $79 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-08-27 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-08-25 | ABBVIE INC. | $2,779 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-08-25 | ABBVIE INC. | $2,300 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-08-19 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-08-07 | ABBVIE INC. | $88 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-07-26 | Galderma Laboratories, L.P. | $6,400 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-26 | Galderma Laboratories, L.P. | $106 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-07-23 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-07-02 | ABBVIE INC. | $543 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-06-26 | ABBVIE INC. | $5,750 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-26 | ABBVIE INC. | $1,150 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-26 | ABBVIE INC. | $225 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-06-20 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-06-18 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-06-17 | ABBVIE INC. | $6,900 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-12 | ABBVIE INC. | $26 | Research payment | In-kind items and services | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rit | 2025 | |
| 2025-06-12 | ABBVIE INC. | $16 | Research payment | In-kind items and services | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rit | 2025 | |
| 2025-06-03 | ABBVIE INC. | $479 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-05-13 | MERZ NORTH AMERICA, INC. | $15 | Food and Beverage | In-kind items and services | Xeomin Biological, Dermatology | 2025 | |
| 2025-05-07 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-05-02 | ABBVIE INC. | $146 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-04-22 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-04-07 | ABBVIE INC. | $267 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-03-27 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-03-25 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-24 | ABBVIE INC. | $115 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-22 | ABBVIE INC. | $128 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-03-07 | ABBVIE INC. | $181 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-02-25 | ABBVIE INC. | $33 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-02-21 | ABBVIE INC. | $900 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-02-11 | ABBVIE INC. | $30 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-02-04 | ABBVIE INC. | $189 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-01-14 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2025 | |
| 2025-01-07 | ABBVIE INC. | $100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2024-12-29 | REVANCE THERAPEUTICS, INC. | $21 | Food and Beverage | In-kind items and services | DAXXIFY Drug, AESTHETICS AND THERAPEUTICS | 2024 | |
| 2024-12-17 | ABBVIE INC. | $25 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2024 | |
| 2024-12-09 | ABBVIE INC. | $1,150 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-12-09 | ABBVIE INC. | $413 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-12-03 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-11-27 | ABBVIE INC. | $3,450 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-11-27 | REVANCE THERAPEUTICS, INC. | $23 | Food and Beverage | In-kind items and services | DAXXIFY Drug, AESTHETICS AND THERAPEUTICS | 2024 | |
| 2024-11-22 | ABBVIE INC. | $55 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-11-15 | ABBVIE INC. | $11,500 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-11-15 | ABBVIE INC. | $35 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-11-11 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-11-08 | ABBVIE INC. | $335 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-11-02 | ABBVIE INC. | $1,026 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-11-02 | ABBVIE INC. | $62 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-11-02 | ABBVIE INC. | $48 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-11-02 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-11-02 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-11-01 | ABBVIE INC. | $202 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-10-09 | ABBVIE INC. | $32 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2024 | |
| 2024-10-04 | ABBVIE INC. | $203 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-09-24 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-09-07 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-09-07 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-20 | ABBVIE INC. | $67 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-07 | ABBVIE INC. | $155 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-08-07 | ABBVIE INC. | $34 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-07-30 | Galderma Laboratories, L.P. | $16 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-07-10 | REVANCE THERAPEUTICS, INC. | $27 | Food and Beverage | In-kind items and services | DAXXIFY Drug, AESTHETICS AND THERAPEUTICS | 2024 | |
| 2024-07-02 | ABBVIE INC. | $118 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-06-18 | ABBVIE INC. | $33 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-10 | ABBVIE INC. | $74 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-08 | Galderma Laboratories, L.P. | $7,000 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-06-06 | ABBVIE INC. | $141 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-05-29 | ABBVIE INC. | $34 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2024 | |
| 2024-05-09 | ABBVIE INC. | $5,850 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-05-06 | ABBVIE INC. | $88 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-05-01 | MERZ NORTH AMERICA, INC. | $5 | Food and Beverage | In-kind items and services | Xeomin Biological, Dermatology | 2024 | |
| 2024-04-26 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-04-24 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2024 | |
| 2024-04-17 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-04-11 | ABBVIE INC. | $68 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-03-22 | ABBVIE INC. | $8 | Education | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2024 | |
| 2024-03-22 | ABBVIE INC. | $8 | Education | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2024 | |
| 2024-03-20 | ABBVIE INC. | $8 | Education | In-kind items and services | 2024 | ||
| 2024-03-20 | ABBVIE INC. | $8 | Education | In-kind items and services | 2024 | ||
| 2024-03-19 | ABBVIE INC. | $25 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-03-12 | REVANCE THERAPEUTICS, INC. | $27 | Food and Beverage | In-kind items and services | DAXXIFY Drug, AESTHETICS AND THERAPEUTICS | 2024 | |
| 2024-03-08 | ABBVIE INC. | $14 | Research payment | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants Wit | 2024 |
| 2024-03-04 | ABBVIE INC. | $4,500 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-03-01 | ABBVIE INC. | $1,800 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-02-26 | MERZ NORTH AMERICA, INC. | $870 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-02-24 | ABBVIE INC. | $707 | Research payment | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-B | 2024 |
| 2024-02-24 | ABBVIE INC. | $70 | Research payment | In-kind items and services | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-B | 2024 | |
| 2024-02-23 | ABBVIE INC. | $326 | Research payment | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-B | 2024 |
| 2024-02-23 | ABBVIE INC. | $130 | Research payment | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-B | 2024 |
| 2024-02-17 | ABBVIE INC. | $703 | Research payment | In-kind items and services | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-B | 2024 | |
| 2024-02-13 | MERZ NORTH AMERICA, INC. | $14 | Food and Beverage | In-kind items and services | Xeomin Biological, Dermatology | 2024 | |
| 2024-02-13 | MERZ NORTH AMERICA, INC. | $5 | Food and Beverage | In-kind items and services | Xeomin Biological, Dermatology | 2024 | |
| 2024-02-06 | ABBVIE INC. | $276 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-02-02 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2024 | |
| 2024-01-05 | ABBVIE INC. | $282 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-01-03 | ABBVIE INC. | $45 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-01-02 | ABBVIE INC. | $3,600 | Research payment | Cash or cash equivalent | Safety and Effectiveness of Juvederm VOLUMA XC Injectable Gel for Cheek Augmentation | 2024 | |
| 2024-01-02 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2024 | |
| 2023-12-29 | ABBVIE INC. | $28 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-12-19 | MERZ NORTH AMERICA, INC. | $19,887 | Research payment | Cash or cash equivalent | Prospective, Multicenter, Controlled, Evaluator-blind, Randomized Study to Investigate the Effectiveness and Safety of D | 2023 | |
| 2023-12-08 | ABBVIE INC. | $1,800 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-12-06 | ABBVIE INC. | $14,850 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-12-06 | ABBVIE INC. | $147 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-12-05 | ABBVIE INC. | $2,250 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-12-05 | ABBVIE INC. | $163 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-12-04 | ABBVIE INC. | $7,200 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-12-04 | ABBVIE INC. | $60 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-11-27 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-11-21 | ABBVIE INC. | $29 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-11-19 | MERZ NORTH AMERICA, INC. | $592 | Travel and Lodging | Cash or cash equivalent | 2023 | ||
| 2023-11-19 | MERZ NORTH AMERICA, INC. | $355 | Food and Beverage | Cash or cash equivalent | 2023 | ||
| 2023-11-19 | MERZ NORTH AMERICA, INC. | $49 | Travel and Lodging | Cash or cash equivalent | 2023 | ||
| 2023-11-17 | Galderma Laboratories, L.P. | $17 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-11-10 | ABBVIE INC. | $734 | Travel and Lodging | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2023 | |
| 2023-11-10 | ABBVIE INC. | $240 | Travel and Lodging | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2023 | |
| 2023-11-10 | ABBVIE INC. | $27 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2023 | |
| 2023-11-10 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2023 | |
| 2023-11-10 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2023 | |
| 2023-11-10 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2023 | |
| 2023-11-09 | ABBVIE INC. | $297 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-11-09 | ABBVIE INC. | $240 | Travel and Lodging | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2023 | |
| 2023-11-09 | ABBVIE INC. | $190 | Travel and Lodging | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2023 | |
| 2023-11-09 | ABBVIE INC. | $60 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2023 | |
| 2023-10-30 | ABBVIE INC. | $8,550 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-10-30 | ABBVIE INC. | $130 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-10-30 | ABBVIE INC. | $52 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-28 | ABBVIE INC. | $191 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-10-28 | ABBVIE INC. | $86 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-28 | ABBVIE INC. | $60 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-28 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-28 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-27 | ABBVIE INC. | $191 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-10-27 | ABBVIE INC. | $135 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-27 | ABBVIE INC. | $93 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-10-27 | ABBVIE INC. | $86 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-27 | ABBVIE INC. | $80 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-10-27 | ABBVIE INC. | $60 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-27 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-27 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-26 | ABBVIE INC. | $191 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-10-25 | ABBVIE INC. | $7,200 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-10-25 | ABBVIE INC. | $67 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-10-19 | ABBVIE INC. | $4,050 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-10-15 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2023 | |
| 2023-10-12 | ABBVIE INC. | $900 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-10-07 | ABBVIE INC. | $793 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-10-07 | ABBVIE INC. | $87 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-10-07 | ABBVIE INC. | $75 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-07 | ABBVIE INC. | $54 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-07 | ABBVIE INC. | $41 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-07 | ABBVIE INC. | $40 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-07 | ABBVIE INC. | $33 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-07 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | 2023 |
The latest 200 records of 555.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-31 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $31,356 | A Multicenter, Blinded, Randomized, Parallel-Group, Comparator-Controlled Study of the Safety and Effectiveness of HArmo | 2025 |
| 2025-12-31 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $916 | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-B | 2025 |
| 2025-12-31 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $8,681 | A Prospective, Open-Label Study to Evaluate Subject Satisfaction with Overall Facial Appearance After Treatment with JUV | 2025 |
| 2025-12-30 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $2,400 | A Study to Evaluate the Safety and Effectiveness of JUVEDERM Products in Adult Participants for the Change of Their Over | 2025 |
| 2025-12-18 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $1,784 | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind | 2025 |
| 2025-12-04 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $366 | A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in | 2025 |
| 2025-12-04 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $51,115 | A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the Cool | 2025 |
| 2025-12-04 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $225 | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of Onabotuli | 2025 |
| 2025-11-12 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $4,262 | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of Onabotuli | 2025 |
| 2025-11-12 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $4,360 | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of Onabotuli | 2025 |
| 2025-11-12 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $3,988 | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of Onabotuli | 2025 |
| 2025-11-12 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $3,341 | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of Onabotuli | 2025 |
| 2025-11-11 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $5,403 | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of Onabotuli | 2025 |
| 2025-11-06 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $5,124 | A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in | 2025 |
| 2025-11-06 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $2,000 | A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in | 2025 |
| 2025-11-06 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $1,012 | A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in | 2025 |
| 2025-11-06 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $2,050 | A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in | 2025 |
| 2025-11-06 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $2,500 | A Study to Evaluate the Safety and Effectiveness of JUVEDERM Products in Adult Participants for the Change of Their Over | 2025 |
| 2025-11-05 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $450 | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of Onabotuli | 2025 |
| 2025-11-05 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $2,498 | A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the Cool | 2025 |
| 2025-11-05 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $1,253 | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind | 2025 |
| 2025-11-05 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $3,500 | A multicenter, double-blind, randomized, parallel-group, controlled study to evaluate the safety and effectiveness of EL | 2025 |
| 2025-11-05 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $9,000 | A Study to Evaluate the Safety and Effectiveness of JUVEDERM Products in Adult Participants for the Change of Their Over | 2025 |
| 2025-10-09 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $96,032 | A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the Cool | 2025 |
| 2025-10-09 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $1,450 | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of Onabotuli | 2025 |
| 2025-10-09 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $2,438 | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind | 2025 |
| 2025-09-04 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $4,945 | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind | 2025 |
| 2025-09-04 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $4,277 | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of Onabotuli | 2025 |
| 2025-09-04 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $5,995 | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of Onabotuli | 2025 |
| 2025-09-04 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $3,988 | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of Onabotuli | 2025 |
| 2025-09-04 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $8,879 | A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the Cool | 2025 |
| 2025-08-21 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $3,405 | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of Onabotuli | 2025 |
| 2025-08-06 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $2,472 | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind | 2025 |
| 2025-08-06 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $9,030 | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of Onabotuli | 2025 |
| 2025-07-08 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $9,458 | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of Onabotuli | 2025 |
| 2025-07-02 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $8,603 | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind | 2025 |
| 2025-06-03 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $11,429 | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of Onabotuli | 2025 |
| 2025-06-03 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $7,315 | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind | 2025 |
| 2025-05-07 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $6,171 | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind | 2025 |
| 2025-05-07 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $12,491 | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of Onabotuli | 2025 |
| 2025-04-03 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $11,272 | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind | 2025 |
| 2025-04-03 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $13,044 | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of Onabotuli | 2025 |
| 2025-04-01 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $3,472 | A Prospective Multi-center Open-label Study to Evaluate Subject Satisfaction and Natural Outcomes Following Administrati | 2025 |
| 2025-03-07 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $6,246 | M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Do | 2025 |
| 2025-03-07 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $13,787 | M24-704 - A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of | 2025 |
| 2025-03-07 | Galderma Laboratories, L.P. | PACIFIC CLINICAL INNOVATIONS INC | $1,000 | A Prospective Open-label Study to Evaluate Safety and Effectiveness of Two Different Reconstitution Volumes of Poly-l-la | 2025 |
| 2025-02-21 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $1,500 | A multicenter real-world evidence study with retrospective chart-review and cross-sectional survey to evaluate the satis | 2025 |
| 2025-02-21 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $1,500 | A multicenter real-world evidence study with retrospective chart-review and cross-sectional survey to evaluate the satis | 2025 |
| 2025-02-21 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $1,500 | A multicenter real-world evidence study with retrospective chart-review and cross-sectional survey to evaluate the satis | 2025 |
| 2025-02-06 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $10,271 | M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Do | 2025 |
| 2025-02-06 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $1,710 | M22-974 - A Prospective Multi-center Open-label Study to Evaluate Subject Satisfaction and Natural Outcomes Following Ad | 2025 |
| 2025-01-02 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $1,592 | M22-974 - A Prospective Multi-center Open-label Study to Evaluate Subject Satisfaction and Natural Outcomes Following Ad | 2025 |
| 2024-12-31 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $13,923 | M22-974 BOTOX GL-FHL-CFL Phase 4 | 2024 |
| 2024-12-31 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $889 | M21-417 BOTOX Ph3 Pivotal MMP | 2024 |
| 2024-12-30 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $5,176 | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind | 2024 |
| 2024-12-05 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $14,303 | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind | 2024 |
| 2024-12-05 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $10,142 | A Prospective Multi-center Open-label Study to Evaluate Subject Satisfaction and Natural Outcomes Following Administrati | 2024 |
| 2024-12-05 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $10,031 | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of Onabotuli | 2024 |
| 2024-11-21 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $824 | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-B | 2024 |
| 2024-11-07 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $26,937 | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-B | 2024 |
| 2024-11-07 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $10,597 | A Prospective Multi-center Open-label Study to Evaluate Subject Satisfaction and Natural Outcomes Following Administrati | 2024 |
| 2024-10-28 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $627 | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind | 2024 |
| 2024-10-10 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $3,000 | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind | 2024 |
| 2024-10-03 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $10,350 | A Prospective Multi-center Open-label Study to Evaluate Subject Satisfaction and Natural Outcomes Following Administrati | 2024 |
| 2024-10-03 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $8,533 | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind | 2024 |
| 2024-09-04 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $5,981 | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind | 2024 |
| 2024-09-04 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $9,066 | A Prospective Multi-center Open-label Study to Evaluate Subject Satisfaction and Natural Outcomes Following Administrati | 2024 |
| 2024-08-28 | ABBVIE INC. | MORADI MD FACE BEAUTIFUL INC | $1,000 | A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants Wit | 2024 |
| 2024-08-22 | ABBVIE INC. | PACIFIC CLINICAL INNOVATION | $2,000 | A single center open label study to assess the efficacy and tolerability of a topical cosmetic hydrating serum | 2024 |
| 2024-08-21 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $7,500 | A multicenter real-world evidence study with retrospective chart-review and cross-sectional survey to evaluate the satis | 2024 |
| 2024-08-02 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $7,958 | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind | 2024 |
| 2024-08-02 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $8,269 | A Prospective Multi-center Open-label Study to Evaluate Subject Satisfaction and Natural Outcomes Following Administrati | 2024 |
| 2024-07-22 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $4,500 | A multicenter real-world evidence study with retrospective chart-review and cross-sectional survey to evaluate the satis | 2024 |
| 2024-07-10 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $32,811 | A single center open label study to assess the efficacy and tolerability of a topical cosmetic hydrating serum | 2024 |
| 2024-07-05 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $8,369 | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind | 2024 |
| 2024-07-05 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $13,794 | A Prospective Multi-center Open-label Study to Evaluate Subject Satisfaction and Natural Outcomes Following Administrati | 2024 |
| 2024-07-03 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $13,500 | A multicenter real-world evidence study with retrospective chart-review and cross-sectional survey to evaluate the satis | 2024 |
| 2024-06-06 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $19,002 | A Prospective Multi-center Open-label Study to Evaluate Subject Satisfaction and Natural Outcomes Following Administrati | 2024 |
| 2024-06-06 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $7,140 | A multicenter, double-blind, randomized, parallel-group, controlled study to evaluate the safety and effectiveness of EL | 2024 |
| 2024-06-05 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $72,164 | A single center open label study to assess the efficacy and tolerability of a topical cosmetic hydrating serum | 2024 |
| 2024-05-23 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $1,000 | A Prospective Multi-center Open-label Study to Evaluate Subject Satisfaction and Natural Outcomes Following Administrati | 2024 |
| 2024-05-23 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $1,400 | A Prospective Multi-center Open-label Study to Evaluate Subject Satisfaction and Natural Outcomes Following Administrati | 2024 |
| 2024-05-15 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $2,000 | A multicenter real-world evidence study with retrospective chart-review and cross-sectional survey to evaluate the satis | 2024 |
| 2024-05-15 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $3,000 | A multicenter real-world evidence study with retrospective chart-review and cross-sectional survey to evaluate the satis | 2024 |
| 2024-05-02 | ABBVIE INC. | PACIFIC CLINICAL INNOVATION | $25,164 | A single center open label study to assess the efficacy and tolerability of a topical cosmetic hydrating serum | 2024 |
| 2024-05-02 | ABBVIE INC. | PACIFIC CLINICAL INNOVATION | $5,000 | A single center open label study to assess the efficacy and tolerability of a topical cosmetic hydrating serum | 2024 |
| 2024-04-17 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $1,500 | A multicenter real-world evidence study with retrospective chart-review and cross-sectional survey to evaluate the satis | 2024 |
| 2024-04-01 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $1,002 | SKM23-TC-INJPP-01: A single center, open-label study to assess the efficacy and tolerability of a topical cosmetic hydra | 2024 |
| 2024-04-01 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $1,482 | SKM23-TC-INJPP-01: A single center, open-label study to assess the efficacy and tolerability of a topical cosmetic hydra | 2024 |
| 2024-03-22 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $22,500 | A multicenter real-world evidence study with retrospective chart-review and cross-sectional survey to evaluate the satis | 2024 |
| 2024-01-01 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $2,142 | SKM23-TC-INJPP-01: A single center, open-label study to assess the efficacy and tolerability of a topical cosmetic hydra | 2024 |
| 2024-01-01 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $1,442 | SKM23-TC-INJPP-01: A single center, open-label study to assess the efficacy and tolerability of a topical cosmetic hydra | 2024 |
| 2024-01-01 | ABBVIE INC. | PACIFIC CLINICAL INNOVATIONS INC | $1,442 | SKM23-TC-INJPP-01: A single center, open-label study to assess the efficacy and tolerability of a topical cosmetic hydra | 2024 |
| 2023-12-31 | ABBVIE INC. | MORADI MD | $550 | A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines | 2023 |
| 2023-12-31 | ABBVIE INC. | MORADI MD | $7,398 | A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants Wit | 2023 |
| 2023-12-05 | ABBVIE INC. | MORADI MD FACE BEAUTIFUL INC | $6,000 | A 26-Week, Multicenter, Open-Label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine | 2023 |
| 2023-11-08 | ABBVIE INC. | MORADI MD FACE BEAUTIFUL INC | $6,491 | A Prospective, Multi-center, Open-label Study to Evaluate Subject Satisfaction and Natural Outcomes Following Administra | 2023 |
| 2023-07-13 | ABBVIE INC. | MORADI MD FACE BEAUTIFUL INC | $1,668 | A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines | 2023 |
| 2023-07-13 | ABBVIE INC. | MORADI MD FACE BEAUTIFUL INC | $257 | A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants Wit | 2023 |
| 2023-06-15 | ABBVIE INC. | MORADI MD FACE BEAUTIFUL INC | $686 | A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants Wit | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Vista, CA, county San Diego County, CA, state California; placed by its city name.
| Measure | Place (city or town) Vista, CA | County San Diego County, CA | State California |
|---|---|---|---|
| Population B01003 | 99,114 | 3,288,774 | 39,287,377 |
| Population, 2020 census P1 | 98,381 | 3,298,634 | 39,538,223 |
| Median age B01002 | 35.9 | 37.3 | 37.9 |
| Under 18 B01001 | 24.3% | 20.9% | 22.0% |
| 65 and over B01001 | 13.0% | 15.4% | 15.7% |
| Households B11001 | 32,323 | 1,171,278 | 13,548,091 |
| Foreign born B05002 | 22.5% | 22.8% | 27.0% |
| Median household income B19013 | $94,975 | $106,268 | $99,122 |
| Median family income B19113 | $105,245 | $122,377 | $113,346 |
| Per capita income B19301 | $42,149 | $51,976 | $49,513 |
| Poverty rate B17001 | 10.5% | 10.3% | 12.0% |
| Unemployment rate B23025 | 6.6% | 6.1% | 6.6% |
| Civilian labor force B23025 | 53,017 | 1,689,384 | 20,068,466 |
| Mean commute (minutes) B08013 | 26.7 | 25.5 | 28.7 |
| Bachelor's degree or higher B15003 | 29.3% | 43.2% | 37.1% |
| Housing units B25001 | 33,536 | 1,250,641 | 14,644,735 |
| Owner-occupied B25003 | 51.7% | 54.6% | 55.9% |
| Renters B25003 | 48.3% | 45.4% | 44.1% |
| Median home value B25077 | $762,400 | $854,700 | $734,700 |
| Median gross rent B25064 | $2,249 | $2,246 | $2,036 |
| White, not Hispanic B03002 | 36.2% | 42.4% | 33.8% |
| Black B03002 | 2.7% | 4.4% | 5.2% |
| Hispanic or Latino B03002 | 49.4% | 34.6% | 40.2% |
| Asian B03002 | 5.6% | 12.1% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Vista, CA.
Comments